Drug Profile
Filgrastim biosimilar - Apexcela
Alternative Names: Leuco-Plus 300; SBS-6002Latest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Apexcela
- Developer Apexcela; Siam Bioscience
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Neutropenia(In volunteers) in Thailand (SC, Injection)
- 05 Aug 2019 Mahidol University in collaboration with INC Research Australia plans a phase I bioequivalence and biosimilarity in Australia and Thailand (ACTRN12619001062112p)
- 10 Jan 2019 Siam Bioscience completes a phase I trial in Neutropenia (In volunteers) in Thailand, before January 2019 (SC) (TCTR20180321003)